beclomethasone, intranasal (Rx)

Brand and Other Names:Beconase AQ, QNASL

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

metered-dose nasal spray suspension

  • 42mcg/actuation (Beconase AQ)

metered-dose nasal spray solution

  • 80mcg/actuation (QNASL)

Allergic Rhinitis

Indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis

Beconase AQ: 1-2 sprays/nostril twice daily (total daily dose: 168-336 mcg/day)

QNASL: 2 sprays/nostril qDay (total daily dose: 320 mcg/day)

Nasal Polyps (Postsurgical Prophylaxis)/ Vasomotor Rhinitis

Beconase AQ: 1-2 sprays/nostril twice daily (total daily dose: 168-336 mcg/day)

Administration

Beconase AQ

  • Shake well before each use
  • Before first use, prime pump by 6 actuations into air
  • If not used for 7 days, reprime pump until fine spray appears

QNASL

  • Before first use, prime pump by spraying into air away from eyes 4 times (dosage counter on canister should read 120 after priming)
  • To prime, hold device upright between thumb and index finger (the canister should be on top, pointing down)
  • If not used for 7 days, reprime pump with 2 sprays before use

Dosage Forms & Strengths

metered-dose nasal spray suspension

  • 42mcg/actuation (Beconase AQ)

metered-dose nasal spray solution

  • 40mcg/actuation (QNASL)
  • 80mcg/actuation (QNASL)

Rhinitis

Indicated for the relief of the symptoms of seasonal or perennial allergic, and nonallergic (vasomotor) rhinitis

Beconase AQ

  • <6 years: Safety and efficacy not established
  • 6-11 years: 1 spray/nostril twice daily (168 mcg/day); may increase to 2 sprays/nostril (336 mcg/day) in patients not adequately responding or those with more severe symptoms; decrease dose to 1 spray/nostril twice daily once adequate control achieved
  • 12 years: As in adults; 1-2 sprays/nostril twice daily (total dose: 168-336 mcg/day)

QNASL

  • <4 years: Safety and efficacy not established
  • 4-11 years: 1 spray (40 mcg/actuation) each nostril qDay (total dose: 80 mcg/day)
  • ≥12 years: As in adults; 2 sprays (80 mcg/actuation) each nostril qDay (total dose: 320 mcg/day)

Administration

Beconase AQ

  • Shake well before each use
  • Before first use, prime pump by 6 actuations into air
  • If not used for 7 days, reprime pump until fine spray appears

QNASL

  • Before first use, prime pump by spraying into air away from eyes 4 times (dosage counter on canister should read 120 after priming)
  • To prime, hold device upright between thumb and index finger (the canister should be on top, pointing down)
  • If not used for 7 days, reprime pump with 2 sprays before use
Next:

Adverse Effects

>10%

Nasopharyngeal irritation (24%)

1-10%

Headache (<5%)

Nausea (<5%)

Lightheadedness (<5%)

Sneezing attacks after administration (4%)

Nasal congestion (<3%)

Nose bleeds (<3%)

Rhinorrhea (<3%)

Increased lacrimation (<3%)

Epistaxis (<3%)

Frequency Not Defined

Nasal mucosa ulceration

Nasal septum perforation

Postmarketing Reports

Blurred vision, glaucoma, cataracts, central serous chorioretinopathy (CSC), loss of taste and smell, hypersensitivity reactions, angioedema, rash, urticaria, and bronchospasm

Previous
Next:

Warnings

Contraindications

Hypersensitivity

Cautions

Larger than recommended doses should be avoided

Monitor for vision change, or with history of increased IOP, glaucoma, or cataracts; consider referral to ophthalmologist in patients who develop ocular symptoms

Potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex

Risk for hypercorticism and adrenal suppression with higher than normal doses

Potential reduction of growth velocity in children

Prolonged corticosteroid use may result in elevated IOP, glaucoma, and/or cataracts

Nasal septal perforation and localized Candida albicans infections of the nose and/or pharynx may occur; when such an infection develops, it may require treatment with appropriate local therapy and discontinuation of treatment

During withdrawal from oral corticosteroids, some patients may experience symptoms of withdrawal, eg, joint and/or muscular pain, lassitude, and depression

If persistent nasopharyngeal irritation occurs, it may be an indication for stopping therapy

As with any long-term treatment, patients this nasal spray therapy over several months or longer should be examined periodically for possible changes in the nasal mucosa

Because of inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use a nasal corticosteroid until healing has occurred

Careful attention must be given when patients previously treated for prolonged periods with systemic corticosteroids are transferred to this drug formulation; this is particularly important in those patients who have associated asthma or other clinical conditions where too rapid a decrease in systemic corticosteroids may cause severe exacerbation of their symptoms

If recommended doses of intranasal beclomethasone are exceeded or if individuals are particularly sensitive or predisposed by virtue of recent systemic steroid therapy, symptoms of hypercorticism may occur, including very rare cases of menstrual irregularities, acneiform lesions, cataracts, and cushingoid features; if such changes occur, therapy should be discontinued slowly consistent with accepted procedures for discontinuing oral steroid therapy

For therapy to be effective in treatment of nasal polyps, the spray must be able to enter nose; therefore, treatment of nasal polyps with this product should be considered adjunctive therapy to surgical removal and/or use of other medications that will permit effective penetration of the drug into the nose; nasal polyps may recur after any form of treatment

Immune suppression

  • Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals; chickenpox and measles, for example, can have more serious or even fatal course in susceptible children or adults using corticosteroids
  • In children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure; how the dose, route, and duration of corticosteroid administration affect risk of developing a disseminated infection is not known; the contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known
  • If exposed to chickenpox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated; if exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated; if chickenpox develops, treatment with antiviral agents may be considered

Previous
Next:

Pregnancy & Lactation

Pregnancy

There are no adequate and well-controlled studies in pregnant women; this drug should be used during pregnancy only if potential benefit justifies potential risk to fetus

Hypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy; such infants should be carefully observed

Animal data

  • Like other corticosteroids, beclomethasone dipropionate was teratogenic and embryocidal in the mouse and rabbit at a subcutaneous dose of 0.1 mg/kg in mice or 0.025 mg/kg in rabbits (approximately equal to the maximum recommended daily intranasal dose in adults on a mg/m2 basis)
  • No teratogenicity or embryocidal effects were seen in rats when exposed to an inhalation dose of 0.1 mg/kg plus oral doses of up to 10 mg/kg per day for a combined dose of 10.1 mg/kg (approximately 240 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis)

Lactation

It is not known whether beclomethasone dipropionate is excreted in human milk; because other corticosteroids are excreted in human milk, exercise caution when this drug is administered to a nursing woman

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Corticosteroid with potent anti-inflammatory properties; elicits effects on various cells, including mast cells and eosinophils; also elicits effects on inflammatory mediators (eg, histamine, eicosanoids, leukotrienes, cytokines)

Absorption

Bioavailability: 44% (43% from swallowing portion of intranasal dose; 1% from nasal absorption)

Peak Plasma Concentration: Undetectable (<50 pg/mL)

Distribution

Protein Bound: 87%

Vd: 20 L; 424 L for B-17-MP metabolite

Metabolism

Metabolites: B-17-MP active metabolite

Metabolized by: Esterase enzymes found in most tissues

Elimination

Half-life: 0.3 hr

Excretion: feces (60%), urine (12%); after oral administration

Previous
Next:

Images

BRAND FORM. UNIT PRICE PILL IMAGE
Beconase AQ nasal
-
42 mcg (0.042 %) aerosol

Copyright © 2010 First DataBank, Inc.

Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.